| Schedule of Carrying Amounts and Fair Values of Financial Instruments |
The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2025 are presented below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements |
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Money market accounts (1) |
|
$ |
8,798 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
8,798 |
|
Marketable securities (2) |
|
|
115 |
|
|
|
— |
|
|
|
— |
|
|
|
115 |
|
|
|
$ |
8,913 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
8,913 |
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Sun Clinical Laboratories, a California corporation (“Sun Labs”) remaining equity interest purchase |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,352 |
|
|
$ |
7,352 |
|
CFC contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
7,026 |
|
|
|
7,026 |
|
CHS contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
7,378 |
|
|
|
7,378 |
|
Other (3) |
|
|
— |
|
|
|
817 |
|
|
|
15 |
|
|
|
832 |
|
Total liabilities |
|
$ |
— |
|
|
$ |
817 |
|
|
$ |
21,771 |
|
|
$ |
22,588 |
|
(1)Included in cash and cash equivalents. (2)Included in prepaid expenses and other current assets. (3)Other consists of other contingent consideration liabilities and the interest rate swap. The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2024 are presented below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements |
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Money market accounts (1) |
|
$ |
3,673 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3,673 |
|
Marketable securities (2) |
|
|
2,378 |
|
|
|
— |
|
|
|
— |
|
|
|
2,378 |
|
I Health call option |
|
|
— |
|
|
|
— |
|
|
|
3,778 |
|
|
|
3,778 |
|
Interest rate collar |
|
|
— |
|
|
|
19 |
|
|
|
— |
|
|
|
19 |
|
Total assets |
|
$ |
6,051 |
|
|
$ |
19 |
|
|
$ |
3,778 |
|
|
$ |
9,848 |
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Sun Labs remaining equity interest purchase |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,352 |
|
|
$ |
7,352 |
|
ADSC contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
4,285 |
|
|
|
4,285 |
|
CFC contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
9,949 |
|
|
|
9,949 |
|
CHS contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
5,643 |
|
|
|
5,643 |
|
Other (3) |
|
|
2,110 |
|
|
|
— |
|
|
|
1,366 |
|
|
|
3,476 |
|
Total liabilities |
|
$ |
2,110 |
|
|
$ |
— |
|
|
$ |
28,595 |
|
|
$ |
30,705 |
|
(1)Included in cash and cash equivalents. (2)Included in prepaid expenses and other current assets. (3)Other consists of other contingent consideration liabilities.
|
| Schedule of Change in Fair Value of Level 3 Liabilities |
The change in the fair value of Level 3 liabilities is recognized in unrealized loss on investments, other income, and general and administrative expenses in the accompanying consolidated statements of income. As of December 31, 2025, the reconciliation of our Level 3 liabilities was as follows (in thousands):
|
|
|
|
|
|
|
Amount |
|
Balance at January 1, 2025 |
|
$ |
28,595 |
|
Additions |
|
|
— |
|
Change in fair value of Level 3 liabilities |
|
|
4,676 |
|
Settlements |
|
|
(11,500 |
) |
Balance at December 31, 2025 |
|
$ |
21,771 |
|
|